Benefits
Testosterone support in men with low levels
Eurycomanone raises total testosterone in men with hypogonadism or age-related testosterone decline. A 2022 meta-analysis confirmed significant testosterone increases, with the strongest effects in men starting with low baseline levels.
Erectile function improvement
In men with age-related androgen decline, eurycomanone combined with regular exercise improved erectile function over 6 months. Effects are most pronounced when paired with strength training rather than as standalone treatment.
Cortisol reduction and stress modulation
Eurycomanone reduces cortisol levels in moderately stressed adults, improving the cortisol-to-testosterone ratio. Particularly relevant for stressed individuals where elevated cortisol suppresses testosterone.
Aromatase inhibition (anti-estrogenic in men)
Eurycomanone inhibits aromatase, the enzyme converting testosterone to estradiol. This preserves circulating testosterone rather than allowing conversion to estrogen — complementary to direct testosterone support.
Athletic performance support
Some evidence suggests eurycomanone supports lean muscle mass and exercise performance, particularly in older or untrained men. Effects in healthy trained athletes are smaller and less consistent.
Libido and sexual function
Clinical use supports libido improvement in men with low testosterone. Effects in men with normal testosterone are less consistent — works through addressing testosterone deficiency, not as a direct aphrodisiac.
Sleep quality in stressed populations
Preliminary evidence suggests eurycomanone may improve sleep quality in stressed adults, likely secondary to cortisol reduction. Not a primary sleep supplement but a relevant secondary benefit.
Mechanism of action
Aromatase inhibition (anti-estrogenic mechanism in men)
Eurycomanone inhibits aromatase — preventing conversion of testosterone to estradiol. Distinct from direct testosterone biosynthesis support: preserves circulating testosterone as testosterone rather than allowing estradiol conversion. Mechanistically aligns with prescription aromatase inhibitors (anastrozole, letrozole) but at a much milder magnitude.
Testosterone biosynthesis support (Leydig cells)
Eurycomanone supports testosterone biosynthesis in Leydig cells — the primary testosterone-producing cell in the testis. Mechanism complement to the aromatase inhibition; together they raise both production and protect from conversion.
Cortisol / HPA axis modulation
Modulates the HPA-axis cortisol response. In moderately stressed populations the cortisol/testosterone ratio improves through both reduced cortisol and supported testosterone.
Quassinoid bioactivity (distinct chemical class)
Quassinoids are a distinct chemical class with multiple biological activities. Eurycomanone is the primary bioactive among Tongkat Ali quassinoids; β-anhydroxonoeurycomalactone, eurycolactone, and other quassinoids contribute additional bioactivity.
9-hydroxycanthin-6-one alkaloid bioactivity
9-hydroxycanthin-6-one is an alkaloid in E. longifolia with additional bioactivity. Contributes to the multi-compound mechanism profile.
SHBG modulation
Sex hormone binding globulin (SHBG) modulation affects free (bioavailable) testosterone. Lower SHBG means more free testosterone available for tissue effects despite similar total testosterone — a mechanism contributing to the clinical efficacy beyond what total testosterone changes alone would predict.
Clinical trials
Clinical evidence on Eurycomanone (Tongkat Ali Quassinoid) for the indications and outcomes described.
Clinical population described in trial publication.
Leisegang K et al. 2022 (, Medicina 58(8):1047). Evidence review and pooled analysis per PRISMA guidelines. 9 studies in review, 5 clinical trials in pooled analysis. Significant increase in total testosterone (SMD 1.352, 95% CI 0.565-2.138, p=0.001). Effect confirmed in hypogonadism subgroup. The most rigorous meta-analytic evidence for any testosterone-supporting herbal supplement.
Clinical evidence on Eurycomanone (Tongkat Ali Quassinoid) for the indications and outcomes described.
Clinical population described in trial publication.
Henkel R et al. 2021 (Maturitas). 6-month 4-arm clinical trial in ADAM (Androgen Deficiency of Aging Males) men. E. longifolia + concurrent training improved erectile function and testosterone in ~50% of participants. Real-world clinical population evidence with exercise combination.
Clinical evidence on Eurycomanone (Tongkat Ali Quassinoid) for the indications and outcomes described.
76 patients with hypogonadism plus late-onset hypogonadism (LOH) on Physta®
Tambi MI 2012. 76 patients with hypogonadism plus late-onset hypogonadism (LOH) on Physta®. Significant testosterone increase observed. Foundational hypogonadism subgroup evidence.